SCHEMBL21471787

SCHEMBL21471787

C=CCN1CCc2cc(C(=O)c3nc4ccccc4o3)sc2-c2ccc(F)cc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 4/20 0.36
CTSL P07711 2/20 0.35
SMN1; SMN2 Q16637 3/20 0.33
MAPT P10636 3/20 0.33
HCRTR1 O43613 2/20 0.33
LMNA P02545 2/20 0.33
HTT P42858 2/20 0.33
NPC1 O15118 1/20 0.33
TSHR P16473 1/20 0.33
RAB9A P51151 1/20 0.33
CTSK P43235 1/20 0.32
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
GABRP O00591 1/20 0.32
GABRD O14764 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRB1 P18505 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21471717 0.83 MAPK14 (0.41) MAPTLMNAHTTKDM4EALDH1A1
SCHEMBL21474620 0.83 MAPK14 (0.41) MAPTLMNAHTTKDM4EALDH1A1
SCHEMBL21471672 0.81 CTSS (0.34) CTSSCTSLHCRTR1CTSK
SCHEMBL20599068 0.80 NOTUM (0.46) LMNAKDM4EALDH1A1GAAL3MBTL1
SCHEMBL21471714 0.80 CHRM2 (0.38) LMNAKDM4EALDH1A1GAAL3MBTL1
SCHEMBL21471602 0.78 GABRP (0.36) SMN1; SMN2HCRTR1LMNAMEN1KMT2A
SCHEMBL21471683 0.77 CHRM2 (0.36) LMNAKDM4EALDH1A1GAAL3MBTL1
SCHEMBL21471675 0.77 ALDH1A1 (0.47) SMN1; SMN2MAPTLMNANPC1RAB9A
SCHEMBL20622402 0.76 HPGD (0.42) SMN1; SMN2MAPTHTTNPC1RAB9A
SCHEMBL21471792 0.75 CHRM2 (0.36) CHRM2CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10975094-B2 Heterocyclic compounds as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2021-04-13 US disclosed
US-20190315766-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2019-10-17 US disclosed
WO-2019199908-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2019-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10975094-B2 Heterocyclic compounds as RSV inhibitors SIRT1, FURIN, SIRT5 CTSS 1057/4885CTSL 1795/4885SMN1; SMN2 382/4885
US-20190315766-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS SIRT1, FURIN, SIRT5 CTSS 1057/4885CTSL 1795/4885SMN1; SMN2 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.